ME00076B - Lijek u čvrstom obliku za oralnu primjenu - Google Patents
Lijek u čvrstom obliku za oralnu primjenuInfo
- Publication number
- ME00076B ME00076B MEP-2008-108A MEP2008108A ME00076B ME 00076 B ME00076 B ME 00076B ME P2008108 A MEP2008108 A ME P2008108A ME 00076 B ME00076 B ME 00076B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical
- agent
- dysuria
- pharmaceuticals
- capsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Ovaj pronalazak obezbedjuje oralni dozni oblik farmaceutika u čvrstom stanju za tretman disurije, koja sadrži, aktivni sastojak, indolin l jedinjenje koje ima α1-adrenoceptor blokirajuću aktivnost i koje je prikazano sa formulom: Ovaj pronalazak obezbedjuje oralni dozni oblik farmaceutika u čvrstom stanju za tretman disurije, koja sadrži, aktivni sastojak, indolin l jedinjenje koje ima α 1-adrenoceptor blokirajuću aktivnost i koje je prikazano sa formulom: njegov proderivat, njegova farmaceutski prihvatljiva so ili njegov farmaceutski prihvatljiv solvat, gde je za navedeni farmaceutik vreme za koje se postigne 85% rastvaranja ne više od 60 minuta u testu rastvorljivosti prema metodi 2(propelerski metod) iz japanske farmakopeje u uslovima u kojima se koristi voda. njegov proderivat, njegova farmaceutski prihvatljiva so ili njegov farmaceutski prihvatljiv solvat, gde je za navedeni farmaceutik vreme za koje se postigne 85% rastvaranja ne više od 60 minuta u testu rastvorljivosti prema metodi 2(propelerski metod) iz japanske farmakopeje u uslovima u kojima se koristi voda.
Claims (18)
1. Oralni dozni oblici farmaceutika u čvrstom stanju za tretman disurije, koji sadrže, kao aktivni sastojak, anindolin jedinjenje koje ima aradrenoceptor blokirajuću aktivnost i prikazano je sa formulom: njegov proderivat, njegova farmaceutski prihvatljiva so ili njegov farmaceutski prihvatljiv solvat, gde vreme za koje se postigne 85 % rastvaranja je ne više od 60 minuta u testu rastvorljivosti prema metodi 2 (propelerski metod) iz japanske farmakopeje u uslovima u kojima se koristi voda kao medijum za testiranje i pri brzini propelera od 50 rpm.
2. Farmaceutik prema zahtevu l, gde vreme rastvaranja 85% nije više od 60 minuta u testu rastvorljivosti prema metodi 2 (propelerski metod) iz japanske farmakopeje u uslovima u kojima se koristi prvi fluid koji je odredjen u testu razgradivosti iz japanske farmakopeje kao medijum za testiranje i pri brzini propelera od 50 rpm.
3. Farmaceutik prema zahtevu 1 ili 2, gde je vreme rastvaranja 85 % ne više od 30 minuta.
4. Farmaceutik prema zahtevu 3, gde je vreme rastvaranja 85 % ne više od 15 minuta
5. Farmaceutik prema bilo kom od zahteva l do 4, koji sadrži D- manitol kao punioc.
6. Farmaceutik prema zahtevu 5, koji dalje sadrži lubrikant.
7. Farmaceutik prema zahtevu 6, gde je kao lubrikant magnezijum stearat, kalcijum stearat ili talk.
8. Farmaceutik prema zahtevu 6, gde je kao lubrikant magnezijum stearat.
9. Farmaceutik prema zahtevu 8, koji dalje sadrži 0.1 do 2 dela natrijum lauril sulfata na 1 deo magnezijum stearata.
10. Farmaceutik prema bilo kom od zahteva 1 do 9, gde je dozna forma u obliku kapsule ili tablete.
11. Farmaceutik prema zahtevu 10, gde kapsula je kapsula sa omotačem sa zaštitom od svetlosti ili je tableta omotana sa agensom za zaštitu od svetlosti.
12. Farmaceutik prema zahtevu 11 , gde je kapsula sa omotačem sa zaštitom od svetlosti, kapsula koja sadrži titanijum oksid .
13. Farmaceutik prema zahtevu ll, gde je agens za zaštitu od svetlosti, agens za zaštitu od svetlosti koji sadrži titanijum oksid.
14. Farmaceutik prema bilo kom od zahteva l do 13, koji dalje sadrži, kao aktivni sastojak, najmanje jedan agens koji je odabran iz grupe koja se sastoji od uradrenoceptor blokirajućeg agensa, antiholinergičnog agensa, antiinflamatornog agensa i antibakterijskog agensa koji se razlikuju od indolin jedinjenje iz zahteva l.
15. Farmaceutik za tretman disurije, koji obuhvata farmaceu tik prema bilo kom od zahteva 1 do 14, u kombinaciji sa farmaceutikom koji uključuje, kao aktivni sastojak, najmanje jedan agens koji je odabran iz grupe koja se sastoji od aradrenoceptor blokirajućeg agensa, antiholinergičnog agensa, antiinflamatornog agensa i antibakterijskog agensa koji se razlikuju od indolin jedinjenje iz zahteva 1.
16. Farmaceutik prema bilo kom od zahteva 1 do 15, koji se koristi za treatman disurije.
17. Farmaceutik prema zahtevu 16, gde je disurija udružena sa blokiranjem organizacije mokraćnog kanala, poremećajima nerva za kontrolu uriniranja ili blokiranjem funkcije mokraćnog kanala.
18. Farmaceutik prema zahtevu 16, gde je disurija udružena sa hipertrofijom prostate, neurogenom bešikom ili poremećajem donjeg dela urinarnog trakta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002364238 | 2002-12-16 | ||
| PCT/JP2003/015837 WO2004054574A1 (ja) | 2002-12-16 | 2003-12-11 | 経口固形医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00076B true ME00076B (me) | 2011-02-10 |
Family
ID=32588229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-108A ME00076B (me) | 2002-12-16 | 2003-12-11 | Lijek u čvrstom obliku za oralnu primjenu |
| MEP-108/08A MEP10808A (en) | 2002-12-16 | 2003-12-11 | Solid drug for oral use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-108/08A MEP10808A (en) | 2002-12-16 | 2003-12-11 | Solid drug for oral use |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20060018959A1 (me) |
| EP (2) | EP1574215B1 (me) |
| JP (1) | JP4633469B2 (me) |
| KR (2) | KR101072909B1 (me) |
| CN (2) | CN100339078C (me) |
| AU (1) | AU2003289320C1 (me) |
| BR (1) | BR0317349A (me) |
| CA (1) | CA2507002C (me) |
| EA (1) | EA008196B1 (me) |
| ES (1) | ES2544560T3 (me) |
| HR (1) | HRP20050544B1 (me) |
| IL (1) | IL169040A (me) |
| IS (1) | IS7929A (me) |
| ME (2) | ME00076B (me) |
| MX (1) | MXPA05006513A (me) |
| NO (1) | NO20053467L (me) |
| NZ (1) | NZ540664A (me) |
| PL (1) | PL220457B1 (me) |
| RS (1) | RS58025B1 (me) |
| TW (2) | TWI325318B (me) |
| UA (2) | UA85359C2 (me) |
| WO (1) | WO2004054574A1 (me) |
| ZA (1) | ZA200504613B (me) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070167511A1 (en) * | 2004-03-05 | 2007-07-19 | Kissei Pharmaceutical Co,. Ltd. | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
| KR100965205B1 (ko) * | 2004-10-05 | 2010-06-24 | 깃세이 야쿠힌 고교 가부시키가이샤 | 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제 |
| WO2008106536A1 (en) * | 2007-02-28 | 2008-09-04 | Kissei Pharmaceuticals Co., Ltd. | Use of silodosin in a once daily administration for treating benign prostatic hyperplasia |
| JP5432720B2 (ja) * | 2007-03-13 | 2014-03-05 | 武田薬品工業株式会社 | ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤 |
| WO2012000926A1 (de) | 2010-06-28 | 2012-01-05 | Ratiopharm Gmbh | Silodosin-cyclodextrin einschlussverbindungen |
| JP2013532651A (ja) | 2010-07-23 | 2013-08-19 | ラティオファルム ゲー・エム・ベー・ハー | シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品 |
| SI2474529T1 (sl) | 2010-12-23 | 2014-12-31 | Sandoz Ag | Kristalne oblike aktivne farmacevtske učinkovine |
| CN102283816B (zh) * | 2011-08-05 | 2013-09-11 | 北京海步国际医药科技发展有限公司 | 西洛多辛缓释片剂及其制备方法 |
| US20140243383A1 (en) * | 2011-08-24 | 2014-08-28 | Cadila Healthcare Limited | Pharmaceutical compositions of silodosin |
| JP6031722B2 (ja) * | 2011-08-31 | 2016-11-24 | 国立大学法人 千葉大学 | 女性の排尿障害の治療剤 |
| MX2014009889A (es) * | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| EP3470397B1 (en) | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| HK1216862A1 (zh) | 2013-03-26 | 2016-12-09 | 橘生药品工业株式会社 | 西洛多辛苦味被掩蔽的口服给药制剂 |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
| KR102206104B1 (ko) * | 2014-04-03 | 2021-01-22 | 한미약품 주식회사 | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 |
| CN103933001A (zh) * | 2014-05-09 | 2014-07-23 | 浙江华海药业股份有限公司 | 一种稳定的赛洛多辛口服固体药物组合物及其制备方法 |
| CN105435233B (zh) * | 2014-08-06 | 2018-05-01 | 江苏正大丰海制药有限公司 | 一种英加韦林的药物组合物 |
| JP6366547B2 (ja) * | 2015-08-03 | 2018-08-01 | 大原薬品工業株式会社 | 光安定性が向上した、プラミペキソール製剤包装体 |
| CN108685867A (zh) * | 2017-04-06 | 2018-10-23 | 昆明积大制药股份有限公司 | 一种赛洛多辛薄膜衣片及其制备方法 |
| EP3354283B1 (en) | 2017-06-20 | 2019-08-07 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical capsule composition comprising silodosin |
| CN111437260A (zh) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | 用于制备盐酸美金刚固态药物组合物的方法 |
| JP7262005B2 (ja) * | 2019-01-25 | 2023-04-21 | 日本ジェネリック株式会社 | シロドシン含有固形組成物及びその製造法 |
| CN114601826B (zh) * | 2022-03-31 | 2024-06-04 | 乐泰药业有限公司 | 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1060073A (en) | 1963-03-02 | 1967-02-22 | Benger Lab Ltd | 2,2,2-trichlorethyl hydrogen succinate and salts |
| US4547498A (en) | 1983-01-06 | 1985-10-15 | Mylan Pharmaceuticals Inc. | Pharmaceutical combination composition and associated method |
| US4757090A (en) * | 1986-07-14 | 1988-07-12 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
| HU200926B (en) * | 1988-10-28 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules |
| EP0600675B1 (en) * | 1992-12-02 | 1998-07-08 | Kissei Pharmaceutical Co., Ltd. | Indoline compounds for the treatment of dysuria |
| US5370878A (en) * | 1993-09-30 | 1994-12-06 | Hallmark Pharmaceuticals, Inc. | Method for preparing a direct compression granulated acetaminophen composition |
| DE69524214T3 (de) | 1994-05-06 | 2008-05-15 | Pfizer Inc. | Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe |
| ES2125198B1 (es) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares. |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| WO1999015202A1 (fr) * | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
| US20020177593A1 (en) * | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
| JP4324266B2 (ja) * | 1999-02-26 | 2009-09-02 | キッセイ薬品工業株式会社 | α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
| US20010053780A1 (en) | 1999-04-30 | 2001-12-20 | Whitaker John S. | Daily treatment for erectile dysfunction using a PDE5 inhibitor |
| JP4014068B2 (ja) * | 1999-07-28 | 2007-11-28 | 芦森工業株式会社 | エアバッグ装置 |
| PE20011178A1 (es) * | 2000-04-07 | 2001-11-19 | Takeda Chemical Industries Ltd | Compuestos heterociclicos y su produccion |
| EP1293206A4 (en) | 2000-05-15 | 2005-09-21 | Kissei Pharmaceutical | LIQUID PREPARATION BASED ON WATER |
| IL156445A0 (en) * | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| JP2001288115A (ja) | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
| JPWO2002069957A1 (ja) * | 2001-03-01 | 2004-07-02 | グレラン製薬株式会社 | フェノフィブラート含有組成物 |
| US6786714B2 (en) * | 2001-04-12 | 2004-09-07 | James W. Haskew | Delivery system for liquid catalysts |
| GB0113843D0 (en) | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
| UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
-
2003
- 2003-12-11 US US10/538,514 patent/US20060018959A1/en not_active Abandoned
- 2003-12-11 MX MXPA05006513A patent/MXPA05006513A/es active IP Right Grant
- 2003-12-11 CA CA2507002A patent/CA2507002C/en not_active Expired - Lifetime
- 2003-12-11 EP EP03780719.5A patent/EP1574215B1/en not_active Revoked
- 2003-12-11 PL PL377495A patent/PL220457B1/pl unknown
- 2003-12-11 AU AU2003289320A patent/AU2003289320C1/en not_active Ceased
- 2003-12-11 NZ NZ540664A patent/NZ540664A/en not_active IP Right Cessation
- 2003-12-11 EP EP11007870A patent/EP2402010A1/en not_active Withdrawn
- 2003-12-11 CN CNB2003801062486A patent/CN100339078C/zh not_active Ceased
- 2003-12-11 CN CN2007100840362A patent/CN101069685B/zh not_active Expired - Lifetime
- 2003-12-11 JP JP2004560618A patent/JP4633469B2/ja not_active Expired - Lifetime
- 2003-12-11 UA UAA200809667A patent/UA85359C2/ru unknown
- 2003-12-11 UA UAA200507046A patent/UA84694C2/ru unknown
- 2003-12-11 ES ES03780719.5T patent/ES2544560T3/es not_active Expired - Lifetime
- 2003-12-11 HR HRP20050544AA patent/HRP20050544B1/hr not_active IP Right Cessation
- 2003-12-11 KR KR1020057010977A patent/KR101072909B1/ko not_active Expired - Lifetime
- 2003-12-11 EA EA200500985A patent/EA008196B1/ru unknown
- 2003-12-11 RS YU20050470A patent/RS58025B1/sr unknown
- 2003-12-11 BR BR0317349-6A patent/BR0317349A/pt not_active Application Discontinuation
- 2003-12-11 KR KR1020107026925A patent/KR101077061B1/ko not_active Expired - Lifetime
- 2003-12-11 ME MEP-2008-108A patent/ME00076B/me unknown
- 2003-12-11 WO PCT/JP2003/015837 patent/WO2004054574A1/ja not_active Ceased
- 2003-12-11 ME MEP-108/08A patent/MEP10808A/xx unknown
- 2003-12-15 TW TW092135358A patent/TWI325318B/zh not_active IP Right Cessation
- 2003-12-15 TW TW098121810A patent/TWI382838B/zh not_active IP Right Cessation
-
2005
- 2005-06-06 ZA ZA200504613A patent/ZA200504613B/en unknown
- 2005-06-07 IL IL169040A patent/IL169040A/en active IP Right Grant
- 2005-07-01 IS IS7929A patent/IS7929A/is unknown
- 2005-07-15 NO NO20053467A patent/NO20053467L/no not_active Application Discontinuation
-
2011
- 2011-11-03 US US13/288,348 patent/US20120064154A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2507002A1 (en) | Solid drug for oral use | |
| AU2003225837B2 (en) | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes | |
| CN108042808B (zh) | 用于治疗中枢系统疾病的包含依匹哌唑或其盐和第二种药物的组合 | |
| IL277272B1 (en) | Rimegepant for cgrp related disorders | |
| HRP20040352A2 (en) | Use of flibanserin in the treatment of sexual disorders | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| AU1451201A (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| IL149496A (en) | Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract | |
| JP2022538911A5 (me) | ||
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JPWO2004066998A1 (ja) | 安定な経口用固形医薬組成物 | |
| JP2575569B2 (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| JP5100619B2 (ja) | ロキソプロフェン含有医薬製剤１ | |
| MA27996A1 (fr) | Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetique | |
| US20220401423A1 (en) | Methods for treating inflammatory bowel disease | |
| PL206268B1 (pl) | Kompozycja przeciwbólowa i/lub przeciwzapalna oraz jej zastosowanie | |
| CA2074580C (en) | Solid pharmaceutical composition for oral administration containing dapiprazole | |
| RU2009107739A (ru) | Способ лечения расстройства терморегуляции | |
| JP6878021B2 (ja) | トリプタンとアスコルビン酸を含有する医薬組成物 | |
| JP2002087960A (ja) | 徐放性錠剤 | |
| TW200401643A (en) | Remedy for hemicrania | |
| PL429246A1 (pl) | Przeciwbólowo - przeciwzapalna kompozycja farmaceutyczna do stosowania w profilaktyce gorączki i/lub bólu, zwłaszcza do stosowania w stanach zapalnych jamy ustnej i gardła | |
| RU2007136896A (ru) | Фармацевтическая композиция, содержащая омегакарбоксиарилзамещенную дифенилмочевину, для лечения рака | |
| RU2010113924A (ru) | Производные 1-аминоалкилциклогексана для лечения кохлеарного тиннитуса |